At the news
? MIXEDIMPACT 6/10 8-K filed Mar 4, 2026 at 16:11 ET
PepGen reported financial results for 2025 and provided updates on its PGN-EDODM1 clinical program for myotonic dystrophy type 1. The company announced a partial clinical hold by the FDA on its FREEDOM2 trial due to preclinical pharmacology and toxicology concerns, while also highlighting positive Phase 1 data and ongoing enrollment in international sites. Financially, the company reduced its net loss year-over-year and maintains a strong cash position into 2027.
- FDA placed a partial clinical hold on the FREEDOM2 Phase 2 trial due to preclinical pharmacology and toxicology data concerns
- Positive Phase 1 FREEDOM trial data showed dose-dependent splicing correction up to 53.7% at 15 mg/kg with generally well-tolerated safety profile
- Company expects data readouts from the 5 mg/kg cohort in Q1 2026 and 10 mg/kg cohort in 2H 2026
- Cash position of $148.5 million as of December 31, 2025, sufficient to fund operations into the second half of 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access